Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Khoury, 2022, The 5th edition of the World Health Organization classification of Haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms, Leukemia., 36, 1703, 10.1038/s41375-022-01613-1 Arber, 2022, International consensus classification of myeloid neoplasms and acute Leukemia: integrating morphological, clinical, and genomic data, Blood, 140, 1200, 10.1182/blood.2022015850 Winter, 2020, Integrating the “Immunome” in the stratification of myelodysplastic syndromes and future clinical trial design, J Clin Oncol, JCO1901823 Sallman, 2019, The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes, Blood., 133, 1039, 10.1182/blood-2018-10-844654 Bernard, 2022, Molecular international prognostic scoring system for myelodysplastic syndromes, NEJM Evid, 1, 10.1056/EVIDoa2200008 Haferlach, 2014, Landscape of genetic lesions in 944 patients with myelodysplastic syndromes, Leukemia., 28, 241, 10.1038/leu.2013.336 Papaemmanuil, 2013, Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood., 122, 3616, 10.1182/blood-2013-08-518886 Malcovati, 2020, SF3B1-mutant MDS as a distinct disease subtype: a proposal from the international working Group for the Prognosis of MDS, Blood., 136, 157, 10.1182/blood.2020004850 Nazha, 2021, Personalized prediction model to risk stratify patients with myelodysplastic syndromes, J Clin Oncol, 39, 3737, 10.1200/JCO.20.02810 Bernard, 2020, Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes, Nat Med, 26, 1549, 10.1038/s41591-020-1008-z Greenberg, 2022, NCCN guidelines® insights: myelodysplastic syndromes, version 3.2022, J Natl Compr Cancer Netw, 20, 106, 10.6004/jnccn.2022.0009 Cazzola, 2020, Myelodysplastic syndromes, N Engl J Med, 383, 1358, 10.1056/NEJMra1904794 Liu, 2022, The coming of age of preclinical models of MDS, Front Oncol, 12 Stubbins, 2022, Inflammation and myeloid malignancy: quenching the flame, Blood., 140, 1067, 10.1182/blood.2021015162 Song, 2019, A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies, Nat Commun, 10, 366, 10.1038/s41467-018-08166-x Reinisch, 2016, A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells, Nat Med, 22, 812, 10.1038/nm.4103 Medyouf, 2014, Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit, Cell Stem Cell, 14, 824, 10.1016/j.stem.2014.02.014 Muguruma, 2011, Establishment of a xenograft model of human myelodysplastic syndromes, Haematologica., 96, 543, 10.3324/haematol.2010.027557 Song, 2021, Combined liver-cytokine humanization comes to the rescue of circulating human red blood cells, Science., 371, 1019, 10.1126/science.abe2485 Papaemmanuil, 2011, Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts, N Engl J Med, 365, 1384, 10.1056/NEJMoa1103283 Bejar, 2011, Clinical effect of point mutations in myelodysplastic syndromes, N Engl J Med, 364, 2496, 10.1056/NEJMoa1013343 Yoshida, 2011, Frequent pathway mutations of splicing machinery in myelodysplasia, Nature., 478, 64, 10.1038/nature10496 Zeidan, 2022, Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the international workshop for myelodysplastic syndromes, Leukemia, 36, 2939, 10.1038/s41375-022-01724-9 Malcovati, 2015, SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts, Blood., 126, 233, 10.1182/blood-2015-03-633537 Fenaux, 2020, Luspatercept in patients with lower-risk myelodysplastic syndromes, N Engl J Med, 382, 140, 10.1056/NEJMoa1908892 Weinberg, 2022, TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML, Blood Adv, 6, 2847, 10.1182/bloodadvances.2021006239 Grob, 2022, Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome, Blood., 139, 2347, 10.1182/blood.2021014472 Bersanelli, 2021, Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes, J Clin Oncol, 39, 1223, 10.1200/JCO.20.01659 Zeidan, 2023, Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy, Leukemia., 37, 240, 10.1038/s41375-022-01766-z Bahaj, 2022, A clinically practicable approach to predict TP53 allelic configurations in myeloid neoplasia, Blood., 140, 2075, 10.1182/blood-2022-162913 Haase, 2019, TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups, Leukemia., 33, 1747, 10.1038/s41375-018-0351-2 Menssen, 2020, Genetics of progression from MDS to secondary leukemia, Blood., 136, 50, 10.1182/blood.2019000942 Lindsley, 2015, Acute myeloid leukemia ontogeny is defined by distinct somatic mutations, Blood., 125, 1367, 10.1182/blood-2014-11-610543 Zeidan, 2019, Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it, Blood Rev, 34, 1, 10.1016/j.blre.2018.09.001 Drazer, 2018, Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies, Blood Adv, 2, 146, 10.1182/bloodadvances.2017013037 Klco, 2021, Advances in germline predisposition to acute leukaemias and myeloid neoplasms, Nat Rev Cancer, 21, 122, 10.1038/s41568-020-00315-z Feurstein, 2021, Germline variants drive myelodysplastic syndrome in young adults, Leukemia., 35, 2439, 10.1038/s41375-021-01137-0 Polprasert, 2015, Inherited and somatic defects in DDX41 in myeloid neoplasms, Cancer Cell, 27, 658, 10.1016/j.ccell.2015.03.017 Tawana, 2015, Disease evolution and outcomes in familial AML with germline CEBPA mutations, Blood., 126, 1214, 10.1182/blood-2015-05-647172 Feurstein, 2022, Germline predisposition variants occur in myelodysplastic syndrome patients of all ages, Blood., 140, 2533, 10.1182/blood.2022015790 Konstantinopoulos, 2020, Germline and somatic tumor testing in epithelial ovarian Cancer: ASCO guideline, J Clin Oncol, 38, 1222, 10.1200/JCO.19.02960 Rio-Machin, 2020, The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants, Nat Commun, 11, 1044, 10.1038/s41467-020-14829-5 Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood., 126, 9, 10.1182/blood-2015-03-631747 Xie, 2014, Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat Med, 20, 1472, 10.1038/nm.3733 Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes, N Engl J Med, 371, 2488, 10.1056/NEJMoa1408617 Genovese, 2014, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N Engl J Med, 371, 2477, 10.1056/NEJMoa1409405 Miller, 2022, Association of clonal hematopoiesis with chronic obstructive pulmonary disease, Blood., 139, 357, 10.1182/blood.2021013531 Jaiswal, 2017, Clonal Hematopoiesis and risk of atherosclerotic cardiovascular disease, N Engl J Med, 377, 111, 10.1056/NEJMoa1701719 Steensma, 2015, Cytopenias + mutations - dysplasia = what?, Blood., 126, 2349, 10.1182/blood-2015-10-672659 Bewersdorf, 2019, From clonal hematopoiesis to myeloid leukemia and what happens in between: will improved understanding lead to new therapeutic and preventive opportunities?, Blood Rev, 37, 10.1016/j.blre.2019.100587 Valent, 2018, ICUS, IDUS, CHIP and CCUS: diagnostic criteria, Separation from MDS and clinical implications, Pathobiology., 1-9 Malcovati, 2017, Clinical significance of somatic mutation in unexplained blood cytopenia, Blood., 129, 3371, 10.1182/blood-2017-01-763425 Steensma, 2018, Clinical consequences of clonal hematopoiesis of indeterminate potential, Blood Adv, 2, 3404, 10.1182/bloodadvances.2018020222 Fabre, 2022, The longitudinal dynamics and natural history of clonal haematopoiesis, Nature., 606, 335, 10.1038/s41586-022-04785-z van Zeventer, 2020, Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals, Blood., 135, 1161 Desai, 2018, Somatic mutations precede acute myeloid leukemia years before diagnosis, Nat Med, 24, 1015, 10.1038/s41591-018-0081-z Gibson, 2017, Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias, Blood., 130, 91, 10.1182/blood-2017-01-764951 Bolton, 2020, Cancer therapy shapes the fitness landscape of clonal hematopoiesis, Nat Genet, 52, 1219, 10.1038/s41588-020-00710-0 Bolton, 2018, Oncologic therapy for solid Tumors alters the risk of clonal Hematopoiesis, Blood., 132, 747, 10.1182/blood-2018-99-119530 Gibson, 2017, Clonal Hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma, J Clin Oncol, 35, 1598, 10.1200/JCO.2016.71.6712 Gillis, 2017, Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study, Lancet Oncol, 18, 112, 10.1016/S1470-2045(16)30627-1 Kwan, 2021, Preexisting TP53-variant clonal Hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with Rucaparib, JAMA Oncol, 7, 1772, 10.1001/jamaoncol.2021.4664 Xie, 2022, Phase II study assessing safety and preliminary efficacy of high dose intravenous ascorbic acid in patients with TET2 mutant clonal Cytopenias of undetermined significance, Blood., 140, 2893, 10.1182/blood-2022-165163 Sallman, 2020, TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype, Blood, 136, 2812, 10.1182/blood.2020006158 Kubasch, 2020, Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents, Leukemia., 34, 1182, 10.1038/s41375-019-0645-z Zeidan, 2018, A multi-center phase I trial of Ipilimumab in patients with myelodysplastic syndromes following Hypomethylating agent failure, Clin Cancer Res, 24, 3519, 10.1158/1078-0432.CCR-17-3763 Zeidan, 2022, A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes, Blood Adv, 6, 2207, 10.1182/bloodadvances.2021005487 Chien, 2021, Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome, Br J Haematol., 195, 378, 10.1111/bjh.17689 Kim, 2022, Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities, Nat Rev Drug Discov, 21, 529, 10.1038/s41573-022-00493-5 Kohlhapp, 2021, Venetoclax increases Intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade, Cancer Discov, 11, 68, 10.1158/2159-8290.CD-19-0759 Bewersdorf, 2020, Immune checkpoint inhibition in myeloid malignancies: moving beyond the PD-1/PD-L1 and CTLA-4 pathways, Blood Rev, 100709 Daver, 2021, T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments, Leukemia., 35, 1843, 10.1038/s41375-021-01253-x Wolf, 2020, TIM3 comes of age as an inhibitory receptor, Nat Rev Immunol, 20, 173, 10.1038/s41577-019-0224-6 Rangachari, 2012, Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion, Nat Med, 18, 1394, 10.1038/nm.2871 Nakayama, 2009, Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation, Blood., 113, 3821, 10.1182/blood-2008-10-185884 Chiba, 2012, Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1, Nat Immunol, 13, 832, 10.1038/ni.2376 Kikushige, 2010, TIM-3 is a promising target to selectively kill acute myeloid Leukemia stem cells, Cell Stem Cell, 7, 708, 10.1016/j.stem.2010.11.014 Kikushige, 2015, A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid Leukemia stem cells and leukemic progression, Cell Stem Cell, 17, 341, 10.1016/j.stem.2015.07.011 Brunner, 2021, Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study, Blood, 138, 244, 10.1182/blood-2021-146039 Zeidan, 2022, Primary results of Stimulus-MDS1: A randomized, double-blind, placebo-controlled phase II study of TIM-3 inhibition with Sabatolimab added to Hypomethylating agents (HMAs) in adult patients with higher-risk myelodysplastic syndromes (MDS), Blood., 140, 2063, 10.1182/blood-2022-158612 Zeidan, 2020, The STIMULUS program: clinical trials evaluating Sabatolimab (MBG453) combination therapy in patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) or acute myeloid Leukemia (AML), Blood., 136, 45, 10.1182/blood-2020-134718 Chao, 2020, Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies, Front Oncol, 9, 1380, 10.3389/fonc.2019.01380 Majeti, 2009, CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells, Cell., 138, 286, 10.1016/j.cell.2009.05.045 Jiang, 2013, CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome, Leuk Res, 37, 907, 10.1016/j.leukres.2013.04.008 Pang, 2013, Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes, Proc Natl Acad Sci U S A, 110, 3011, 10.1073/pnas.1222861110 Sallman, 2022, S166: Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1B study results, HemaSphere., 6, 67, 10.1097/01.HS9.0000843556.59348.1d Daver, 2022, Phase I/II study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute myeloid Leukemia (AML) and relapsed/refractory (R/R) AML, Blood., 140, 141, 10.1182/blood-2022-170188 Kauder, 2018, ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile, PLoS One, 13, 10.1371/journal.pone.0201832 Lakhani, 2021, Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study, Lancet Oncol, 22, 1740, 10.1016/S1470-2045(21)00584-2 Garcia-Manero, 2021, Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02), Blood, 138, 2601, 10.1182/blood-2021-146547 Garcia-Manero, 2022, Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with Azacitidine and Venetoclax in patients with acute myeloid Leukemia (ASPEN-05): results from phase 1a dose escalation part, Blood., 140, 9046, 10.1182/blood-2022-157606 Ansell, 2021, Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies, Clin Cancer Res, 27, 2190, 10.1158/1078-0432.CCR-20-3706 Wang, 2018, VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML, Oncoimmunology., 7, 10.1080/2162402X.2018.1469594 Mostböck, 2022, Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by fc-receptor interaction, Front Immunol, 13, 10.3389/fimmu.2022.862757 Kim, 2022, Programmed Death-1 homolog (PD-1H/VISTA) blockade confers a synergistic anti-Leukemia effect with PD-1 blockade, Blood., 140, 87, 10.1182/blood-2022-158314 Villarroel-Espindola, 2018, Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer, Clin Cancer Res, 24, 1562, 10.1158/1078-0432.CCR-17-2542 Gao, 2017, VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer, Nat Med, 23, 551, 10.1038/nm.4308 Stahl, 2020, Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis, Haematologica., 105, 102, 10.3324/haematol.2019.219345 Passweg, 2011, Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99, J Clin Oncol, 29, 303, 10.1200/JCO.2010.31.2686 Grayson, 2021, VEXAS syndrome, Blood., 137, 3591 Comont, 2022, Azacitidine for patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry, Br J Haematol, 196, 969, 10.1111/bjh.17893 Mekinian, 2022, A phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML, Leukemia., 36, 2739, 10.1038/s41375-022-01698-8 Yeaton, 2022, The impact of inflammation-induced tumor plasticity during myeloid transformation, Cancer Discov, 12, 2392, 10.1158/2159-8290.CD-21-1146 Mangan, 2018, Targeting the NLRP3 inflammasome in inflammatory diseases, Nat Rev Drug Discov, 17, 588, 10.1038/nrd.2018.97 Bennett, 2022, IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies, Curr Opin Hematol, 29, 8, 10.1097/MOH.0000000000000693 Trowbridge, 2021, Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS, J Exp Med, 218, 10.1084/jem.20201544 Smith, 2019, U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies, Nat Cell Biol, 21, 640, 10.1038/s41556-019-0314-5 Choudhary, 2022, Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations, Elife., 11 McLemore, 2022, Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes. JCI, Insight., 7 Garcia-Manero, 2022, Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome, J Clin Oncol, 40, 7016, 10.1200/JCO.2022.40.16_suppl.7016 Chen, 2022, Epigenetic and transcriptional regulation of innate immunity in cancer, Cancer Res, 82, 2047, 10.1158/0008-5472.CAN-21-3503 Sugita, 2022, Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia, Nat Commun, 13, 2227, 10.1038/s41467-022-29668-9 Ravandi, 2020, Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML), J Clin Oncol, 38, 7508, 10.1200/JCO.2020.38.15_suppl.7508 Subklewe, 2019, Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Blood, 134, 833, 10.1182/blood-2019-127977 Pan, 2022, Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis, Cell., 185 DiNardo, 2020, Azacitidine and venetoclax in previously untreated acute myeloid leukemia, N Engl J Med, 383, 617, 10.1056/NEJMoa2012971 Wei, 2022, Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy, Blood., 140, 2754, 10.1182/blood.2022016963 Slape, 2012, Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome, Blood., 120, 2475, 10.1182/blood-2012-05-430736 Garcia, 2021, Molecular responses are observed across mutational Spectrum in treatment-Naïve higher-risk myelodysplastic syndrome patients treated with Venetoclax plus Azacitidine, Blood., 138, 241, 10.1182/blood-2021-145613 Garcia, 2020, Safety, efficacy, and patient-reported outcomes of Venetoclax in combination with Azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study, Blood., 136, 55, 10.1182/blood-2020-139492 Bazinet, 2022, Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-Centre, dose-escalation, dose-expansion, phase 1-2 study, Lancet Haematol, 9, 10.1016/S2352-3026(22)00216-2 Zeidan, 2023, A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes, Am J Hematol., 98, 272, 10.1002/ajh.26771 Huang, 2021, Epigenetic deregulation in myeloid malignancies, Blood., 138, 613, 10.1182/blood.2019004262 Bewersdorf, 2019, Epigenetic therapy combinations in acute myeloid leukemia: what are the options?, Ther Adv Hematol, 10, 10.1177/2040620718816698 Figueroa, 2009, MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation, Blood., 114, 3448, 10.1182/blood-2009-01-200519 DiNardo, 2014, Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents, Leuk Lymphoma, 55, 1925, 10.3109/10428194.2013.855309 Prebet, 2014, Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia intergroup trial E1905, J Clin Oncol, 32, 1242, 10.1200/JCO.2013.50.3102 Glass, 2017, Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers, Cancer Discov, 7, 868, 10.1158/2159-8290.CD-16-1032 Telonis, 2022, MIR retrotransposons link the epigenome and the transcriptome of coding genes in acute myeloid leukemia, Nat Commun, 13, 6524, 10.1038/s41467-022-34211-x Yang, 2022, DNA methylation profiles capture clinical and molecular heterogeneity of MDS and can be harnessed for the development of robust biomarkers predictive of response to Azacitidine, Blood., 140, 9769, 10.1182/blood-2022-163704 Meldi, 2015, Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia, J Clin Invest, 125, 1857, 10.1172/JCI78752 Papaemmanuil, 2016, Genomic classification and prognosis in acute myeloid Leukemia, N Engl J Med, 374, 2209, 10.1056/NEJMoa1516192 Challen, 2011, Dnmt3a is essential for hematopoietic stem cell differentiation, Nat Genet, 44, 23, 10.1038/ng.1009 Jeong, 2018, Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo, Cell Rep, 23, 1, 10.1016/j.celrep.2018.03.025 Yang, 2016, DNMT3A loss drives enhancer Hypomethylation in FLT3-ITD-associated Leukemias, Cancer Cell, 29, 922, 10.1016/j.ccell.2016.05.003 Ko, 2010, Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2, Nature., 468, 839, 10.1038/nature09586 Moran-Crusio, 2011, Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation, Cancer Cell, 20, 11, 10.1016/j.ccr.2011.06.001 Cimmino, 2017, Restoration of TET2 function blocks aberrant self-renewal and Leukemia progression, Cell., 170 Thol, 2010, IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis, Haematologica., 95, 1668, 10.3324/haematol.2010.025494 Gross, 2010, Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations, J Exp Med, 207, 339, 10.1084/jem.20092506 Lu, 2012, IDH mutation impairs histone demethylation and results in a block to cell differentiation, Nature., 483, 474, 10.1038/nature10860 Stein, 2017, Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia, Blood., 130, 722, 10.1182/blood-2017-04-779405 Montesinos, 2022, Ivosidenib and Azacitidine in IDH1-mutated acute myeloid Leukemia, N Engl J Med, 386, 1519, 10.1056/NEJMoa2117344 DiNardo, 2018, Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML, N Engl J Med, 378, 2386, 10.1056/NEJMoa1716984 Sallman, 2022, Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): updated enrollment and results of a phase 1 dose-escalation and expansion substudy, J Clin Oncol, 40, 7053, 10.1200/JCO.2022.40.16_suppl.7053 DiNardo, 2022, Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome, Blood Adv. Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. Sun, 2018, HOXA9 reprograms the enhancer landscape to promote Leukemogenesis, Cancer Cell, 34 Bernt, 2011, MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L, Cancer Cell, 20, 66, 10.1016/j.ccr.2011.06.010 Heimbruch, 2021, DOT1L inhibitors block abnormal self-renewal induced by cohesin loss, Sci Rep, 11, 7288, 10.1038/s41598-021-86646-9 Rau, 2016, DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia, Blood., 128, 971, 10.1182/blood-2015-11-684225 Stein, 2018, The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia, Blood., 131, 2661, 10.1182/blood-2017-12-818948 Bewersdorf, 2022, Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic, Genes Dev, 36, 259, 10.1101/gad.349368.122 Krivtsov, 2019, A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged Leukemia, Cancer Cell, 36 Zhang, 2021, Targeting LSD1 for acute myeloid leukemia (AML) treatment, Pharmacol Res, 164, 10.1016/j.phrs.2020.105335 Saleque, 2007, Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1, Mol Cell, 27, 562, 10.1016/j.molcel.2007.06.039 Cusan, 2018, LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPalpha-dependent enhancers in AML, Blood., 131, 1730, 10.1182/blood-2017-09-807024 Barth, 2019, LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML, Leukemia., 33, 1411, 10.1038/s41375-018-0375-7 Kohrogi, 2021, LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα, Blood Adv, 5, 2305, 10.1182/bloodadvances.2020003521 Watts, 2018, The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS, Blood, 132, 2721, 10.1182/blood-2018-99-115411 DiNardo, 2021, Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML), Blood, 138, 4430, 10.1182/blood-2021-146791 Devillier, 2015, Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes, Oncotarget., 6, 8388, 10.18632/oncotarget.3460 Döhner, 2022, Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel, Blood., 140, 1345, 10.1182/blood.2022016867 Balasubramani, 2015, Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex, Nat Commun, 6, 7307, 10.1038/ncomms8307 Asada, 2018, Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis, Nat Commun, 9, 2733, 10.1038/s41467-018-05085-9 Wang, 2021, Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia, Nat Can, 2, 515, 10.1038/s43018-021-00199-4 Campagne, 2019, BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation, Nat Commun, 10, 348, 10.1038/s41467-018-08255-x Uni, 2019, Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification, Leukemia., 33, 191, 10.1038/s41375-018-0198-6 Steensma, 2021, Imetelstat achieves meaningful and durable transfusion Independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study, J Clin Oncol, 39, 48, 10.1200/JCO.20.01895 Dong, 2014, Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes, Leuk Res, 38, 830, 10.1016/j.leukres.2014.04.008 Wang, 2018, Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells, Blood Adv, 2, 2378, 10.1182/bloodadvances.2018022012 Baerlocher, 2015, Telomerase inhibitor Imetelstat in patients with essential Thrombocythemia, N Engl J Med, 373, 920, 10.1056/NEJMoa1503479 Corporation, 2023 Chen, 2021, Splicing factor mutations in hematologic malignancies, Blood., 138, 599, 10.1182/blood.2019004260 Bejar, 2015, Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the international working Group for Prognosis in MDS-Molecular Committee, Blood., 126, 907, 10.1182/blood.V126.23.907.907 Ohgami, 2015, Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations, Mod Pathol, 28, 706, 10.1038/modpathol.2014.160 Thol, 2012, Frequency and prognostic impact of mutations in <em>SRSF2</em>, <em>U2AF1</em>, and <em>ZRSR2</em> in patients with myelodysplastic syndromes, Blood., 119, 3578, 10.1182/blood-2011-12-399337 Nadeu, 2016, Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia, Blood., 127, 2122, 10.1182/blood-2015-07-659144 El Marabti, 2021, Therapeutic modulation of RNA splicing in malignant and non-malignant disease, Trends Mol Med, 27, 643, 10.1016/j.molmed.2021.04.005 Seiler, 2018, H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers, Nat Med, 24, 497, 10.1038/nm.4493 Steensma, 2021, Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms, Leukemia., 35, 3542, 10.1038/s41375-021-01328-9 Han, 2017, Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15, Science., 356, eaal3755, 10.1126/science.aal3755 Assi, 2018, Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, Cancer., 124, 2758, 10.1002/cncr.31398 Bewersdorf, 2022, A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes, Blood., 140, 9065, 10.1182/blood-2022-156830 Lu, 2021, Pharmacologic modulation of RNA splicing enhances anti-tumor immunity, Cell., 184 Flach, 2021, Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations, Haematologica., 106, 2906, 10.3324/haematol.2020.254193 Singh, 2020, SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications, Leukemia., 34, 2525, 10.1038/s41375-020-0753-9 Nguyen, 2018, Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndromes, Cancer Res, 78, 5363, 10.1158/0008-5472.CAN-17-3970 Chen, 2018, The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations, Mol Cell, 69 Nagata, 2019, Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes, Nat Commun, 10, 5386, 10.1038/s41467-019-13001-y Zhang, 2016, Clinicopathological features and mutational analysis of patients with aplastic Anemia and Hypoplastic myelodysplastic syndrome, Blood., 128, 1993, 10.1182/blood.V128.22.1993.1993 Stahl, 2022, An agenda to advance research in MDS: a TOP 10 priority List from the first international workshop in MDS (iwMDS), Blood Adv. Zeidan, 2023, Consensus proposal for revised international working group response criteria for higher risk myelodysplastic syndromes, Blood., 10.1182/blood.2022018604 Chen, 2021, Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia, Leuk Lymphoma, 62, 1226, 10.1080/10428194.2020.1861267 Estey, 2022, Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal, Blood., 139, 323, 10.1182/blood.2021011304 Ball, 2022, A product of “clash of titans” or true reflection of disease biology? Validation of 2022 WHO and ICC classifications in a large dataset of patients with myelodysplastic syndrome, Blood., 140, 1118, 10.1182/blood-2022-170158 Rodriguez-Meira, 2022, Deciphering <em>TP53</em> mutant cancer evolution with Single-Cell Multi-Omics, bioRxiv Platzbecker, 2018, Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial, Lancet Oncol, 19, 1668, 10.1016/S1470-2045(18)30580-1 Miles, 2020, Single-cell mutation analysis of clonal evolution in myeloid malignancies, Nature., 587, 477, 10.1038/s41586-020-2864-x Dillon, 2021, Impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome. JCO precis, Oncol., 265 Duncavage, 2022, Genomic profiling for clinical decision making in myeloid neoplasms and acute Leukemia, Blood., 140, 2228, 10.1182/blood.2022015853 Bolton, 2018, Managing clonal hematopoiesis in patients with solid Tumors, J Clin Oncol, JCO1800331 Arber, 2016, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood., 127, 2391, 10.1182/blood-2016-03-643544 Stengel, 2022, Interplay of TP53 allelic state, blast count and karyotype on survival of patients with AML and MDS, Blood., 140, 2073, 10.1182/blood-2022-159388 Gómez, 2022, TP53 allelic state in myelodysplastic syndromes with 5q deletion, Blood., 140, 6949, 10.1182/blood-2022-165257 Zeidan, 2022, A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML, Blood Adv, 6, 2219, 10.1182/bloodadvances.2021006138 Sallman, 2021, Eprenetapopt (APR-246) and Azacitidine in TP53-mutant myelodysplastic syndromes, J Clin Oncol, 39, 1584, 10.1200/JCO.20.02341 Cluzeau, 2021, Eprenetapopt plus Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid Leukemia: a phase II study by the Groupe francophone des Myélodysplasies (GFM), J Clin Oncol, 39, 1575, 10.1200/JCO.20.02342 Adès, 2022, Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML, Blood Adv, 6, 5132, 10.1182/bloodadvances.2022007334